ライフサイエンスコーパス: FVC

1 FVC decline from its post-transplant baseline provides v

2 FVC measurements may not be appropriate for monitoring d

3 FVC missed 71.4% of dysplastic lesions per lesion wherea

4 FVC modeling, including 1,960 individuals, yielded simil

5 FVC% has acceptable test-retest reliability, and we have

6 FVC% improvement by >/=MCID was associated with either s

7 as FUSE missed 25.0% per lesion (P = .0001); FVC missed 75.0% of dysplastic lesions per subject and F

8 d (FEV(1) -0.011L, [95% CI -0.05 to 0.028L], FVC -0.012L [95% CI -0.060 to 0.036] and FEV(1)/FVC rati

9 confidence interval (CI) -0.104 to -0.032), FVC (adj. difference -0.043L, 95% CI -0.086 to -0.0009)

10 6 to -0.0009) and post-bronchodilator FEV(1)/FVC ratio (adj.

11 -0.012L [95% CI -0.060 to 0.036] and FEV(1)/FVC ratio -0.0012 [95% CI -0.0072 to 0.0047L]).

12 omposite mortality, hospitalization, and 10% FVC decline.

13 ses in FEV1 (95.5 +/- 7.0 to 100.7 +/- 5.9), FVC (93.6 +/- 8.9 to 98.6 +/- 8.3%), FRC (45.4 +/- 18.5

14 ity (11 [4%] vs 17 [5%]; p=0.4251), absolute FVC decrease by 10% or more (49 [17%] vs 64 [19%]; p=0.4

15 essed by spirometry (FEV1:FVC >/=0.70 and an FVC above the lower limit of the normal range after bron

16 r FEV1 (79.8 +/- 10.6 vs. 95.5 +/- 7.0%) and FVC (82.4 +/- 13.2 vs. 93.7 +/- 8.9%) compared with cont

17 beta=-0.0012 (95% CI: -0.0019, -0.0006) and FVC: beta=-0.0022 (95% CI: -0.0031, -0.0014) per BMI-inc

18 al adrenoreceptor blockade increased FBF and FVC at rest and during exercise in both groups, although

19 oth groups, although the increase in FBF and FVC from rest to steady-state exercise was similar in yo

20 hus the age-associated impairment in FBF and FVC persisted.

21 prebronchodilator percent predicted FEV1 and FVC (-0.36 [95% CI, -0.62 to -0.10] and -0.21 [95% CI, -

22 5 z scores and 0.9 z scores in both FEV1 and FVC (with no difference in FEV1/FVC) in Indian-semiurban

23 w levels, was associated with lower FEV1 and FVC and an accelerated rate of lung function decline.

24 s associated with slower decline in FEV1 and FVC by 22.5 (95% CI: 10.8, 34.2) and 37.9 (95% CI: 22.1,

25 0.5 z-scores ( approximately 5%) in FEV1 and FVC compared with African American peers from the third

26 etary risk factors, slower rates of FEV1 and FVC decline by 23.6 (95% CI: 16.6, 30.7) and 37.3 (95% C

27 Concurrent FEV1 and FVC decline identifies patients with fulminant, rapid de

28 ients (29%) demonstrated concurrent FEV1 and FVC decline.

29 Subjects recorded daily FEV1 and FVC for up to 490 days.

30 patients with concurrent decline in FEV1 and FVC had significantly higher PRM(PD) than control subjec

31 lso associated with odds ratios for FEV1 and FVC less than the lower limit of normal (LLN) (defined a

32 ted with reduced postbronchodilator FEV1 and FVC percent predicted.

33 owding, and pollution exposure) and FEV1 and FVC trajectories between ages 43 and 60-64 years were in

34 Serial FEV1 and FVC values were studied among 205 bilateral lung transpl

35 At baseline, the FEV1 and FVC were 29+/-7% and 77+/-18% of the predicted values, r

36 provements in 4-year growth of both FEV1 and FVC were associated with declining levels of nitrogen di

37 FEV1 and FVC were measured up to two times between 1995 and 2011

38 eading to a proportionately smaller FEV1 and FVC without respiratory impairment, as shown by the norm

39 ls of nitrogen dioxide (P<0.001 for FEV1 and FVC) and of particulate matter with an aerodynamic diame

40 Lower lung function measures (FEV1 and FVC) were associated with higher PM2.5 and NOx levels in

41 od (referred to as 4-year growth in FEV1 and FVC).

42 ) and less than 10 mum (P<0.001 for FEV1 and FVC).

43 ticipants with COPD, a reduction in FEV1 and FVC, and an increase in R5-20 were associated with an in

44 fe exposures impact on both midlife FEV1 and FVC.

45 tified a mean of 0.37 dysplastic lesions and FVC identified a mean of 0.13 dysplastic lesions (P = .0

46 [95% CI, -0.62 to -0.21], respectively) and FVC (-0.19 [95% CI, -0.25 to -0.07] and -0.25 [95% CI, -

47 When stratified by baseline FVC (<70% or >/=70%), disease progression, mortality, FV

48 line FEV1 was achieved earlier than baseline FVC (median, 296 vs. 378 d; P < 0.0001).

49 sit was associated with lower levels of both FVC and FEV1, with effect estimates increasing up to 6-7

50 y whether lung function decline, assessed by FVC and FEV1, is accelerated in women who undergo menopa

51 ed to groups that underwent FUSE followed by FVC.

52 ars of age and higher forced vital capacity (FVC) and FEV1 values at age 15 years (0.12 [95% CI, 0.08

53 volume in 1 s (FEV1), forced vital capacity (FVC) and FEV1/FVC with 1000 Genomes Project (phase 1)-im

54 decrease in predicted forced vital capacity (FVC) by 10% or more, a decrease in 6 min walk distance (

55 very P = 0.0007) with Forced Vital Capacity (FVC) downstream of BANP on chromosome 16 that shows evid

56 n 1 second (FEV1) and forced vital capacity (FVC) during that period (referred to as 4-year growth in

57 ociated with FEV1 and forced vital capacity (FVC) in adolescents with and without asthma, whereas MS

58 FEV1 and its ratio to forced vital capacity (FVC) in never-smokers.

59 iated with changes in forced vital capacity (FVC) in two cohorts.

60 Change in forced vital capacity (FVC) is widely accepted as a surrogate for mortality and

61 ronchodilator FEV1 to forced vital capacity (FVC) of 0.70 or less, a smoking history of at least 10 p

62 plant, or decrease in forced vital capacity (FVC) of 10% or greater or decrease in diffusion capacity

63 in 1 second (FEV1) to forced vital capacity (FVC) of less than 0.70 as assessed by spirometry after b

64 D was defined as FEV1/forced vital capacity (FVC) of less than 70% and less than the lower limit of n

65 wer decrease in their forced vital capacity (FVC) over time as compared with untreated ALS patients,

66 rations with FEV1 and forced vital capacity (FVC) percent predicted, FEV1/FVC ratio, and PC20, adjust

67 The FEV1/forced vital capacity (FVC) ratio is used as a criterion for airflow obstructio

68 ad a lower FEV1, FEV1/forced vital capacity (FVC) ratio, and forced expiratory volume after exhaling

69 rpg) was defined as a forced vital capacity (FVC) z score of less than -1.64 or an increase in FVC of

70 e in 1 second (FEV1), forced vital capacity (FVC), and 6-minute walk distance.

71 vital capacity (VC), forced vital capacity (FVC), and forced expiratory volume in 1 second (FEV1).

72 measurements included forced vital capacity (FVC), carbon monoxide diffusing capacity, and 6 min walk

73 volume in 1 s (FEV1), forced vital capacity (FVC), FEV1/FVC, and diffusing capacity for carbon monoxi

74 in 1 sec (FEV(1)) or forced vital capacity (FVC), or both, after administration of a shortacting bet

75 function parameters (forced vital capacity (FVC), pre- and postbronchodilator FEV1, residual volume

76 tratified by baseline forced vital capacity (FVC), serum LOXL2 (sLOXL2) concentrations, and pirfenido

77 rcentage of predicted forced vital capacity (FVC).

78 al rate of decline in forced vital capacity (FVC).

79 one-second (FEV1) and forced vital capacity (FVC).

80 ne second (FEV1 ) and forced vital capacity (FVC)] (n = 414).

81 ume in 1 s (FEV1) and forced vital capacity (FVC)] was measured at 2 and up to 5 visits between 1992

82 n 1 second (FEV1) to forced volume capacity (FVC).

83 lume in 1 s [FEV1] to forced vital capacity [FVC] <70%, bronchodilator reversibility >/=12%, fraction

84 lume in 1 s [FEV1] to forced vital capacity [FVC] ratio <0.7 in patients with symptoms or a new diagn

85 rst second [FEV1] and forced vital capacity [FVC]) and a decrease in pulse wave velocity (PWV) and au

86 lung function (FEV1, forced vital capacity [FVC], and forced expiratory flow between 25% and 75% [FE

87 me in 1 second [FEV1]/forced vital capacity [FVC], Pearson r = -0.69, P < .001; percentage predicted

88 ut conventional forward-viewing colonoscopy (FVC) detects dysplasia with low levels of sensitivity.

89 oss-over, tandem colonoscopy study comparing FVC vs FUSE in 52 subjects with IBD undergoing surveilla

90 and calculated forearm vascular conductance (FVC) at rest, during steady-state stimulus conditions (p

91 calculated changes in vascular conductance (FVC) to intra-arterial infusion of phenylephrine (PE; al

92 ermodilution), forearm vascular conductance (FVC, venous occlusion plethysmography) and cutaneous vas

93 Changes in forearm vascular conductance (FVC; Doppler ultrasound, brachial intra-arterial pressur

94 hange of FVC at 3 months suggests that daily FVC may be of value as a primary endpoint in short proof

95 Vs, also were associated with improved FeNO, FVC growth, and absenteeism, but these findings were pri

96 ]), mean FEV1 (-166 ml [-332, -1]) and FEV1 /FVC ratio (-4.6%, [-8.1, -1.1]) at 12 years.

97 e AA/AG genotypes had a 5% decrease in FEV1 /FVC (P<.001).

98 es (AA/AG), were associated with lower FEV1 /FVC in subjects with asthma (beta=-1.25, CI: -2.14,-0.35

99 ted with offspring airway obstruction (FEV1 /FVC < 75%).

100 a status and the PAI-1 polymorphism on FEV1 /FVC (P=.03).

101 cle metaboreflex, in 18 COPD patients (FEV1 /FVC ratio < 70%), 9 also classified as chronically hyper

102 correlation between postbronchodilator FEV1 /FVC and periostin levels (-0.276, P < 0.05).

103 .05), but not with FEV1 (% predicted), FEV1 /FVC or bronchodilator reversibility.

104 ed as post-bronchodilator spirometric (FEV1 /FVC) ratio <lower limit of normal.

105 The decrease in the FEV1 /FVC ratio associated with the risk genotype was modified

106 bronchodilator and post-bronchodilator FEV1, FVC, FEV1/FVC, and maximum mid-expiratory flow (MMEF).

107 ed nitric oxide (FeNO), lung function (FEV1, FVC), and absenteeism were also collected monthly (1,768

108 limitation of activity, slightly lower FEV1, FVC, and inspiratory capacity, and greater airway-wall t

109 FEV1/FVC and %NVQ had the highest correlation (r = 0.82).

110 xpiratory phase [FEF25-75%], P = 0.016; FEV1/FVC, P = 0.009) and increased risk for current asthma (o

111 greater (OR, 1.72; 95% CI, 1.14-2.59), FEV1/FVC ratio decrements (OR, -0.22 SDU; 95% CI, -0.36 to -0

112 but the proportion of patients with an FEV1/FVC ratio <0.7 decreased at 6, 12, 18, and 24 months (55

113 w limitation phenotype (A Limit) had an FEV1/FVC z score of less than -1.64 but not A Trpg.

114 lso conducted meta-analysis of FEV1 and FEV1/FVC GWAS in the COPDGene, ECLIPSE, and GenKOLS cohorts (

115 Post bronchodilator FEV1 and FEV1/FVC ratio are considered the standard assessment of airf

116 lution computed tomographic images, and FEV1/FVC ratios less than 0.8 or greater than 0.9 (<0.7 or >0

117 Associations between smoking and FEV1/FVC ratios were different between asthma phenotypes (int

118 (lowest p-value = 2.17 x 10(-11)), and FEV1/FVC was associated with a genomic region on chromosome 4

119 DLCO, FEV1, and FEV1/FVC were found to be valuable parameters in determining

120 (FEV1), forced vital capacity (FVC) and FEV1/FVC with 1000 Genomes Project (phase 1)-imputed genotype

121 measures (post-bronchodilator FEV1 and FEV1/FVC).

122 hysematous changes were DLCO, FEV1, and FEV1/FVC, in that order.

123 as greatest for subjects whose baseline FEV1/FVC value was closest to the diagnostic threshold, and t

124 in the significant associations between FEV1/FVC and 2 genes: ADAM19 and HTR4.

125 COPD was defined as post-bronchodilator FEV1/FVC <0.7.

126 tion was defined as post-bronchodilator FEV1/FVC less than 0.70.

127 ically defined as a post-bronchodilator FEV1/FVC less than the lower limit of normal.

128 riables of pre- and post-bronchodilator FEV1/FVC ratio, FEV1 (liters), FEV1 (% predicted), forced exp

129 ebronchodilator and post-bronchodilator FEV1/FVC ratios among subjects without asthma and those with

130 ratio of FEV1 to forced vital capacity (FEV1/FVC) in the general population.

131 ultivariate prediction model containing FEV1/FVC and the standard deviation of Pao2 (as significant p

132 dicators were associated with decreased FEV1/FVC (beta = -1.5% to -1.7% per z score) but not with FEV

133 asthma had approximately 10% decreased FEV1/FVC ratios (P < .05).

134 Mediation analyses suggested that FEV1, FEV1/FVC ratio, and FEF75 might explain 7% (95% CI, 2% to 10%

135 s were negatively associated with FEV1, FEV1/FVC, and MMEF.

136 tween endothelial dysfunction and FEV1, FEV1/FVC, low-attenuation area/visual emphysema, and diffusin

137 A6/7] (p-value = 3.49 x 10(-8)) and for FEV1/FVC on chromosome 1 [TGFB2] (p-value = 8.99 x 10(-9)), 4

138 nces: -0.22 to -0.27 SD units (SDU) for FEV1/FVC ratio and -0.21 to -0.33 SDU for FEF25-75) compared

139 s (FEV1), forced vital capacity (FVC), FEV1/FVC, and diffusing capacity for carbon monoxide (DLCO).

140 ator and post-bronchodilator FEV1, FVC, FEV1/FVC, and maximum mid-expiratory flow (MMEF).

141 ge at birth had a lower FEV1 but higher FEV1/FVC ratio (P < .05).

142 Decline in FEV1/FVC ratio is associated with underfilling of the left he

143 Decline in FEV1/FVC ratio was associated with smaller left atrial intern

144 index was associated with a decrease in FEV1/FVC ratios among adolescents with insulin resistance.

145 MS had an approximately 2% decrease in FEV1/FVC ratios, adolescents with asthma had an approximately

146 oth FEV1 and FVC (with no difference in FEV1/FVC) in Indian-semiurban and Indian-rural children, resp

147 ronic Pseudomonas aeruginosa infection, FEV1/FVC (forced vital capacity), PA:A greater than 1, and pr

148 lso significantly associated with lower FEV1/FVC (P = 0.04), its contribution relative to PRM(FSA) in

149 s associated with higher FEV1 but lower FEV1/FVC ratio and FEF75 in childhood (P < .05).

150 changed FEV1 (P = 0.94), yielding lower FEV1/FVC ratios (P < 0.001).

151 t smoking was not associated with lower FEV1/FVC ratios among those with childhood-onset persistent a

152 between 0 and 3 months of age and lower FEV1/FVC ratios at age 8 and 15 years (-0.13 [95% CI, -0.16 t

153 a, whereas MS was associated with lower FEV1/FVC ratios, with a more pronounced decrease found among

154 asthma were both associated with lower FEV1/FVC ratios.

155 nourished African children had a normal FEV1/FVC ratio but significant reductions of approximately 0.

156 tory impairment, as shown by the normal FEV1/FVC ratio.

157 c output (beta = -0.070 L/min per SD of FEV1/FVC decline; P = 0.03).

158 The lowest quartile of FEV1/FVC ratio at 7 years was associated with ACOS (odds rati

159 ere shown to have an additive effect on FEV1/FVC levels in the genetic risk score analysis; were asso

160 een endothelial dysfunction and FEV1 or FEV1/FVC in HeartSCORE participants (all P > 0.05).

161 e minimum set of SNPs that best predict FEV1/FVC in the Hutterites and used the GRAIL algorithm to mi

162 Measured and predicted FEV1/FVC ratios were obtained, with calculation of z scores f

163 vital capacity (FVC) percent predicted, FEV1/FVC ratio, and PC20, adjusting for seasonality and confo

164 Decline in FVC with preserved FEV1/FVC ratio is associated with left ventricular hypertroph

165 ociated with reduced FEV1 to FVC ratio (FEV1/FVC), hyperinflation, and alveolar enlargement, but litt

166 ons within 1 year before index CT scan, FEV1/FVC, and chronic P aeruginosa infection (1.14 [0.80-1.62

167 rnal dimension (beta = -0.038 cm per SD FEV1/FVC decline; P < 0.0001) and lower cardiac output (beta

168 nction measures at age 1 month, but the FEV1/FVC genetic risk score was associated with reduced FEF50

169 We identified associations between the FEV1/FVC ratio and 5 common genetic variants in the identific

170 Reduction of the FEV1/FVC ratio can support the diagnosis of asthma; however,

171 multiple regression and found that the FEV1/FVC ratio decreased 1.2% per 6-point increase in the wri

172 exposures were not associated with the FEV1/FVC ratio or bronchodilator response.

173 We wanted to estimate the FEV1/FVC ratio z score threshold with optimal accuracy for th

174 The FEV1/FVC remained unchanged over time, but the proportion of

175 io of FEV1 to forced expiratory volume [FEV1/FVC] less than 70% plus FEV1 % predicted less than 80%)

176 function and analyzed associations with FEV1/FVC among 3983 participants of European ancestry from Co

177 ationship of the PAI-1 risk allele with FEV1/FVC by multivariate linear regression, stratified by ast

178 tified 1 common variant associated with FEV1/FVC independent of the sentinel ADAM19 GWAS hit and supp

179 rations were negatively associated with FEV1/FVC ratio (P < .05).

180 mitting wheeze was only associated with FEV1/FVC ratio decrements (OR, -0.15 SDU; 95% CI, -0.25 to -0

181 C42EP4 and DOCK5 transcript counts with FEV1/FVC ratio together support a role of CDC42 in the TH1 po

182 Associations with FEV1/FVC ratio were weak or absent.

183 LF number correlated negatively with FEV1/FVC.

184 r 4 additional loci had P < 10(-5) with FEV1/FVC.

185 We defined COPD as FEV1:FVC less than the lower limit of normal.

186 ary function as assessed by spirometry (FEV1:FVC >/=0.70 and an FVC above the lower limit of the norm

187 630 children who completed spirometry, FEV1:FVC was less than 70% in ten (2%) children, of whom only

188 tervention group tended to have higher final FVC measurements, the change between the first and last

189 n 2.5 mum (P= 0.008 for FEV1 and P<0.001 for FVC) and less than 10 mum (P<0.001 for FEV1 and FVC).

190 and we have provided the MCID estimates for FVC% in SSc-ILD based changes at 12 months from baseline

191 Slope estimates were greater for FVC than FEV1, and increased with cumulative exposure.

192 clinically important differences (MCID) for FVC% predicted in the Scleroderma Lung Study I and II.

193 e similar (21.2 min for FUSE vs 19.1 min for FVC; P = .32), but withdrawal time was significantly lon

194 mates for the pooled cohort at 12 months for FVC% improvement ranged from 3.0 % to 5.3% and for worse

195 and post-menopausal women, in particular for FVC, beyond the expected age change.

196 we evaluated the test-retest reliability for FVC% predicted (FVC%; screening vs. baseline) using intr

197 The associations were similar for FVC and persisted among lifetime never-smokers.

198 significantly lower for FUSE (0.19) than for FVC (0.83; P < .0001).

199 ficantly longer for FUSE (15.8 min) than for FVC (12.0 min) (P = .03).

200 edicted and lower limit of normal values for FVC and FEV1 than those in other Hispanic/Latino backgro

201 hildren in the caffeine group had values for FVC below the fifth centile (11% vs. 28%; odds ratio, 0.

202 LA progression was associated with a greater FVC decline when compared with participants without ILA

203 h across childhood is associated with higher FVC and FEV1 values.

204 re higher in patients with advanced IPF (ie, FVC <70%) who were treated with antacids than not treate

205 hospitalization, or a decline of >/= 10% in FVC.

206 h or a categorical decrease from baseline in FVC % predicted, in the intention-to-treat population, i

207 [19%]; p=0.4411), or mean observed change in FVC (% predicted -4.9% [SD 6.4] vs -5.5% [7.2], p=0.3355

208 In the exploratory analysis, change in FVC indicated that clinical benefit from addition of ace

209 The primary end point was the change in FVC or death at week 52.

210 The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with

211 bserved variation in 48-week slope change in FVC, UCSD SOBQ, and 6MWD.

212 ities are modestly correlated with change in FVC.

213 rval (CI), -21 to -10%]), greater changes in FVC and FEV1 (0.02 [95% CI, 0.003 to 0.05] and 0.01 [95%

214 1 (P < 0.001) and 1.55 ml/yr less decline in FVC (P < 0.001).

215 P < 0.001) and 3.27 ml/yr greater decline in FVC (P < 0.001).

216 he proportion of patients with no decline in FVC (P<0.001).

217 36-12.11 vs HR for 10% or greater decline in FVC 4.68, 1.83-11.99).

218 ciated with an additional rate of decline in FVC and FEV1 of between 0.5% and 0.9% per year, respecti

219 Decline in FVC from peak was associated with larger left ventricula

220 vely, the adjusted annual rate of decline in FVC in patients treated with placebo was -225.7 and -221

221 ed C statistic </=0.63 for >/=10% decline in FVC or death, </=0.68 for >/=20-U increase in UCSD SOBQ

222 ce in the adjusted annual rate of decline in FVC was 117.0 ml/yr (95% confidence interval, 76.3-157.8

223 Decline in FVC was associated with diastolic dysfunction (odds rati

224 The rate of decline in FVC was highly predictive of outcome and subsequent mort

225 Decline in FVC with preserved FEV1/FVC ratio is associated with lef

226 fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progr

227 al did not have a 10% or greater decrease in FVC (30 vs eight).

228 2.0-15 mL decrease) and a 16 ml decrease in FVC (95% CI: 7.0-24 mL decrease) per 1 kg/m(2) higher BM

229 centration was associated with a decrease in FVC (forced vital capacity) and FEV1 (forced expiratory

230 t and 58 (11%) had a categorical decrease in FVC of at least 10%.

231 tal admission and at least a 10% decrease in FVC with all-cause mortality.

232 associated with a 3.7% absolute decrement in FVC% (95% confidence interval [CI] = 0.9-6.6%), a 1.6-fo

233 with a significant (p=0.0050) improvement in FVC in the Yale cohort.

234 z score of less than -1.64 or an increase in FVC of 10% of predicted value or greater with bronchodil

235 e interval [CI], 55 to 225), the increase in FVC was greater by 347 ml (95% CI, 107 to 588), and the

236 admission and a 10% or greater reduction in FVC across strata of baseline physiological impairment.

237 ow obstruction was associated with increased FVC (P = 0.004) but unchanged FEV1 (P = 0.94), yielding

238 truction, aging is associated with increased FVC and CT-defined functional small airway abnormality r

239 Mean initial FVC did not differ significantly between the interventio

240 ociated with a 38.9 ml (-70.4 to -7.3) lower FVC.

241 lergic sensitisation, elevated IgE and lower FVC in childhood, which may reflect effects of lower pre

242 n prior-year PM2.5 was associated with lower FVC (-21.8 ml; -43.9 to 0.2) and higher odds of FEV1 les

243 om a major roadway was associated with lower FVC (-98.6 ml; -176.3 to -21.0).

244 apid length growth was associated with lower FVC and FVC1 values at age 15 years.

245 d BC exposure were all associated with lower FVC.

246 The adjusted mean FVC decline was increased by -10.2 ml/yr (95% confidence

247 function using a peak flow meter to measure FVC in both groups of patients.

248 e change between the first and last measured FVC was not statistically significant (0.29 and 0.25 L,

249 or >/=70%), disease progression, mortality, FVC, 6MWD, and hospital admission did not differ between

250 nome-wide association study meta-analysis of FVC in 52,253 individuals from 26 studies and followed u

251 ship between mortality and rate of change of FVC at 3 months suggests that daily FVC may be of value

252 allograft dysfunction, whereas the course of FVC change has been less acknowledged and rarely used.

253 as a predictor for mortality, independent of FVC decline, has not been well defined.

254 rometry permits more frequent measurement of FVC than does hospital-based assessment, which therefore

255 benefit with respect to the preservation of FVC in patients with idiopathic pulmonary fibrosis with

256 Reliability of FVC%, assessed at a mean of 34 days, was 0.93 for the po

257 ft ventricular mass (beta = 6.05 g per SD of FVC decline; P < 0.0001) and greater cardiac output (bet

258 cardiac output (beta = 0.109 L/min per SD of FVC decline; P = 0.001).

259 D estimates for improvement and worsening of FVC% with patient reported outcomes (PROs) and computer-

260 progression defined by 48-week worsening of FVC, dyspnea (University of California, San Diego Shortn

261 Decline in FEV1 or FVC from their respective post-transplant baselines occu

262 SNPs were found with P < 10(-5) for FEV1 or FVC.

263 % to -1.7% per z score) but not with FEV1 or FVC.

264 ffect on PEF (L/min), weekly home-based PEF, FVC, and FEV1.

265 and 2.9 [0.9], respectively) and percentage FVC (beta [SE], 12.1 [2.8] and 11.5 [3.4], respectively)

266 ta [SE], 1.5 [0.61]; P = .02) and percentage FVC (beta [SE], 5.2 [2.2]; P = .02) for selected vitamin

267 ed with higher ALSFRS-R scores or percentage FVC.

268 ajectories were correlated with postbaseline FVC trajectory (r = -0.30, 95% CI = -0.46 to -0.11, P =

269 The adjusted % predicted FVC improved from baseline to 24 months by 2.19 in the m

270 01; 1.2% decrease in percentage of predicted FVC; 95% CI, 0.6-1.8%; P < 0.001) and decreased diffusin

271 s or more in the percentage of the predicted FVC or who died; there was also a relative increase of 1

272 test-retest reliability for FVC% predicted (FVC%; screening vs. baseline) using intra-class correlat

273 CLAD when compared with those with preserved FVC (P < 0.0001; 3-yr survival estimates 9% vs. 48%, res

274 5% was associated with significantly reduced FVC decline over 48 weeks versus no emphysema or emphyse

275 ded intensity handgrip exercise, the reduced FVC and subsequently lower skeletal muscle blood flow in

276 ysema extent (28 to 65%) showed the smallest FVC decline, with a difference of 3.32% at Week 48 versu

277 Subsequent FVC decline in patients with an initial isolated FEV1 de

278 This subsequent FVC decline was associated with worsening FEV1 and lower

279 ted FEV1 decline, with 80% later meeting the FVC decline criterion.

280 The course of the % FVC did not differ significantly between the two treatme

281 rived from the joint model showed that the % FVC improved significantly in both the mycophenolate mof

282 LE: Aging is associated with reduced FEV1 to FVC ratio (FEV1/FVC), hyperinflation, and alveolar enlar

283 xed effects modeling of the ratio of FEV1 to FVC was used to identify distinct lung function trajecto

284 c measures (GSTCD and PTCH1) were related to FVC.

285 e assigned randomly to groups that underwent FVC followed by FUSE, and 25 were assigned to groups tha

286 a percentage of the predicted normal value (FVC %) over the course of 24 months, was assessed in a m

287 Moreover, the VC, FVC, and FEV1 were more highly correlated with R5, X5, F

288 ) were significantly correlated with the VC, FVC, and FEV1.

289 is was associated with greater lung volumes (FVC, vital capacity, and total lung capacity) and lesser

290 We compared FUSE vs FVC in the detection of dysplasia in patients with IBDs.

291 and CVC were similar between groups, whereas FVC increased to a greater extent in young adults (P < 0

292 rovements in some PROs, QILD, and QLF, while FVC% worsening >/=MCID was associated with statistically

293 nome-wide significance (P < 5 x 10(-8)) with FVC in or near EFEMP1, BMP6, MIR129-2-HSD17B12, PRDM11,

294 or early-life exposures were associated with FVC decline.

295 teristics further revealed associations with FVC % predicted, and oral corticosteroid or antileukotri

296 There were similar associations with FVC.

297 Patients with FVC decline at CLAD onset had significantly worse surviv

298 y significantly associated with z FEV1 and z FVC (P < 0.0005).

299 e, there were no differences in z FEV1 and z FVC between Indian-urban and UK-Indian children.

300 hildren had significantly lower z FEV1 and z FVC than UK-Indian children (P < 0.0005), when expressed